Cargando…
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a heterogeneous cholangiopathy characterized by progressive biliary fibrosis. RNA sequencing of liver tissue from patients with PSC (n = 74) enrolled in a 96‐week clinical trial was performed to identify associations between biological pat...
Autores principales: | Gindin, Yevgeniy, Chung, Chuhan, Jiang, Zhaoshi, Zhou, Jing Zhu, Xu, Jun, Billin, Andrew N., Myers, Robert P., Goodman, Zachary, Landi, Abdolamir, Houghton, Michael, Green, Richard M., Levy, Cynthia, Kowdley, Kris V., Bowlus, Christopher L., Muir, Andrew J., Trauner, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048608/ https://www.ncbi.nlm.nih.gov/pubmed/32745270 http://dx.doi.org/10.1002/hep.31488 |
Ejemplares similares
-
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2019) -
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019) -
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2023) -
The immunobiology of primary sclerosing cholangitis
por: Aron, Jonathan H., et al.
Publicado: (2009) -
Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)